Replies to post #243586 on Biotech Values

[vinmantoo]

There are two ways of looking at this from ENTA’s perspective. The bearish take is that COVID antivirals aren’t needed in adults under age 65 lacking major risk factors, limiting the addressable market for EDP-235.

Agreed. In addition, I scanned the paper and chances for hospitalization for those under 65 and not immunized was greatly reduced by Paxloid treatment. That means the market is broader than just the over 65. By the way, the over 65 with risk factors is still a pretty high market.

[WorstLuck]

A third view is that assigning bullish or bearish to ENTA is overreacting. To wit, this thread:

How should a trial that is underpowered be reported? Here is Washington Post reporting on Paxlovid trial in NEJM:

"Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors"

— Peter Suzman (@Biomaven) August 25, 2022